Optogenetic Neuromodulation

International Review of Neurobiology

Volumn 107, Issue , 2012, Pages 185-205

  Kalanithi, Paul S A ^a   Henderson, Jaimie M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Neuromodulation; Optogenetics; Parkinson's disease

Indexed keywords

OPSIN; VIRUS VECTOR;

ACCURACY; ANIMAL BEHAVIOR; ARTICLE; BOLD SIGNAL; BRAIN DEPTH STIMULATION; CORPUS STRIATUM; EXPERIMENTAL MODEL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENE PRODUCT; GENE THERAPY; GENE VECTOR; GENETIC MANIPULATION; HUMAN; MOTOR CORTEX; NEUROLOGIC DISEASE; NEUROMODULATION; NONHUMAN; OPSIN GENE; OPTOGENETICS; OXYGEN BLOOD LEVEL; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; RHESUS MONKEY; TRANSLATIONAL RESEARCH;

EID: 84872385423     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-404706-8.00010-3     Document Type: Chapter

References (64)

1. Bekar L., Libionka W., Tian G.-F., Xu Q., Torres A., Wang X., et al. Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. Nature Medicine 2007, 14(1):75-80. 10.1038/nm1693.
2. Berndt A., Yizhar O., Gunaydin L.A., Hegemann P., Deisseroth K. Bi-stable neural state switches. Nature Neuroscience 2009, 12:229-234. 10.1038/nn.2247.
3. Bernstein J.G., Han X., Henninger M.A., Ko E.Y., Qian X., Franzesi G.T., et al. Prosthetic systems for therapeutic optical activation and silencing of genetically-targeted neurons. Proceedings-Society of Photo-Optical Instrumentation Engineers 2008, 6854:68540H. 10.1117/12.768798.
4. Boyden E.S., Zhang F., Bamberg E., Nagel G., Deisseroth K. Millisecond-timescale, genetically targeted optical control of neural activity. Nature Neuroscience 2005, 8(9):1263-1268. 10.1038/nn1525.
5. Breit S., Schulz J.R.B., Benabid A.L. Deep brain stimulation. Cell and Tissue Research 2004, 318(1):275-288. 10.1007/s00441-004-0936-0.
6. Burger C., Gorbatyuk O.S., Velardo M.J., Peden C.S., Williams P., Zolotukhin S., et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Molecular Therapy 2004, 10(2):302-317. 10.1016/j.ymthe.2004.05.024.
7. Chow B.Y., Han X., Dobry A.S., Qian X., Chuong A.S., Li M., et al. High-performance genetically targetable optical neural silencing by light-driven proton pumps. Nature 2010, 463(7277):98-102. 10.1038/nature08652.
8. Churchland M.M., Cunningham J.P., Kaufman M.T., Foster J.D., Nuyujukian P., Ryu S.I., et al. Neural population dynamics during reaching. Nature 2012, 487(7405):51-56. 10.1038/nature11129.
9. Ciesielska A., Mittermeyer G., Hadaczek P., Kells A.P., Forsayeth J., Bankiewicz K.S. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Molecular Therapy 2009, 19(5):922-927. Nature Publishing Group. 10.1038/mt.2010.248.
10. Deisseroth K., Feng G., Majewska A.K., Miesenböck G., Ting A., Schnitzer M.J. Next-generation optical technologies for illuminating genetically targeted brain circuits. The Journal of Neuroscience 2006, 26(41):10380-10386. 10.1523/JNEUROSCI.3863-06.2006.
11. Diester I., Kaufman M.T., Mogri M., Pashaie R., Goo W., Yizhar O., et al. An optogenetic toolbox designed for primates. Nature Neuroscience 2011, 14(3):387-397. Nature Publishing Group.
12. Dittgen T., Nimmerjahn A., Komai S., Licznerski P., Waters J., Margrie T.W., et al. Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(52):18206-18211. 10.1073/pnas.0407976101.
13. Dong J.Y., Fan P.D., Frizzell R.A. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Human Gene Therapy 1996, 7(17):2101-2112. 10.1089/hum.1996.7.17-2101.
14. Dong B., Nakai H., Xiao W. Characterization of genome integrity for oversized recombinant AAV vector. Molecular Therapy 2010, 18(1):87-92. 10.1038/mt.2009.258.
15. Feldbauer K., Zimmermann D., Pintschovius V., Spitz J., Bamann C., Bamberg E. Channelrhodopsin-2 is a leaky proton pump. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(30):12317-12322. 10.1073/pnas.0905852106.
16. Fenno L., Yizhar O., Deisseroth K. The development and application of optogenetics. Annual Review of Neuroscience 2011, 34:389-412. 10.1146/annurev-neuro-061010-113817.
17. Gradinaru V., Mogri M., Thompson K.R., Henderson J.M., Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science 2009, 324(5925):354-359. 10.1126/science.1167093.
18. Gradinaru V., Thompson K.R., Deisseroth K. eNpHR: A Natronomonas halorhodopsin enhanced for optogenetic applications. Brain Cell Biology 2008, 36(1-4):129-139. 10.1007/s11068-008-9027-6.
19. Gradinaru V., Zhang F., Ramakrishnan C., Mattis J., Prakash R., Diester I., et al. Molecular and cellular approaches for diversifying and extending optogenetics. Cell 2010, 141(1):154-165. 10.1016/j.cell.2010.02.037.
20. Gunaydin L.A., Yizhar O., Berndt A., Sohal V.S., Deisseroth K., Hegemann P. Ultrafast optogenetic control. Nature Neuroscience 2010, 13(3):387-392. 10.1038/nn.2495.
21. Han X., Chow B.Y., Zhou H., Klapoetke N.C., Chuong A., Rajimehr R., et al. A high-light sensitivity optical neural silencer: Development and application to optogenetic control of non-human primate cortex. Frontiers in Systems Neuroscience 2011, 5:18. 10.3389/fnsys.2011.00018.
22. Han X., Qian X., Bernstein J.G., Zhou H.-H., Franzesi G.T., Stern P., et al. Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. Neuron 2009, 62(2):191-198. 10.1016/j.neuron.2009.03.011.
23. Henckaerts E., Dutheil N., Zeltner N., Kattman S., Kohlbrenner E., Ward P., et al. Site-specific integration of adeno-associated virus involves partial duplication of the target locus. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(18):7571-7576. 10.1073/pnas.0806821106.
24. Hochberg L.R., Bacher D., Jarosiewicz B., Masse N.Y., Simeral J.D., Vogel J., et al. Reach and grasp by people with tetraplegia using a neurally controlled robotic arm. Nature 2012, 485(7398):372-375. 10.1038/nature11076.
25. Kaplitt M.G. Gene therapy clinical trials in the human brain. Protocol development and review of current applications. Frontiers of Neurology and Neuroscience 2009, 25:180-188. 10.1159/000209498.
26. Karbowski J. Thermodynamic constraints on neural dimensions, firing rates, brain temperature and size. Journal of Computational Neuroscience 2009, 27(3):415-436. 10.1007/s10827-009-0153-7.
27. Kells A.P., Forsayeth J., Bankiewicz K.S. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: Anterograde distribution of AAV2 vectors in the primate brain. Neurobiology of Disease 2012, 48(2):228-235. (1-8, Elsevier Inc). 10.1016/j.nbd.2011.10.004.
28. 2+-permeable channelrhodopsin CatCH. Nature Neuroscience 2011 Apr, 14(4):513-518. Epub 2011 Mar 13.
29. Kravitz A.V., Freeze B.S., Parker P.R.L., Kay K., Thwin M.T., Deisseroth K., et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010, 466(7306):622-626. 10.1038/nature09159.
30. Kumar M., Keller B., Makalou N., Sutton R.E. Systematic determination of the packaging limit of lentiviral vectors. Human Gene Therapy 2001, 12(15):1893-1905. 10.1089/104303401753153947.
31. Lee J.H., Durand R., Gradinaru V., Zhang F., Goshen I., Kim D.-S., et al. Global and local fMRI signals driven by neurons defined optogenetically by type and wiring. Nature 2010, 465(7299):788-792. 10.1038/nature09108.
32. LeWitt P.A., Rezai A.R., Leehey M.A., Ojemann S.G., Flaherty A.W., Eskandar E.N., et al. AAV2-GAD gene therapy for advanced Parkinson's disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurology 2011, 10(4):309-319. 10.1016/S1474-4422(11)70039-4.
33. Long M.A., Fee M.S. Using temperature to analyse temporal dynamics in the songbird motor pathway. Nature 2008, 456(7219):189-194. 10.1038/nature07448.
34. Markakis E.A., Vives K.P., Bober J., Leichtle S., Leranth C., Beecham J., et al. Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Molecular Therapy 2010, 18(3):588-593. 10.1038/mt.2009.286.
35. Matsuno-Yagi A., Mukohata Y. Two possible roles of bacteriorhodopsin; a comparative study of strains of Halobacterium halobium differing in pigmentation. Biochemical and Biophysical Research Communications 1977, 78(1):237-243.
36. Mattis J., Tye K.M., Ferenczi E.A., Ramakrishnan C., O'Shea D.J., Prakash R., et al. Principles for applying optogenetic tools derived from direct comparative analysis of microbial opsins. Nature Methods 2012, 9(2):159-172. 10.1038/nmeth.1808.
37. Meissner W., Leblois A., Hansel D., Bioulac B., Gross C.E., Benazzouz A., et al. Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. Brain 2005, 128(Pt 10):2372-2382. 10.1093/brain/awh616.
38. Monahan P.E., Samulski R.J. Adeno-associated virus vectors for gene therapy: More pros than cons. Molecular Medicine Today 2000, 6(11):433-440.
39. Moser E., Mathiesen I., Andersen P. Association between brain temperature and dentate field potentials in exploring and swimming rats. Science 1993, 259(5099):1324-1326.
40. Nagel G., Ollig D., Fuhrmann M., Kateriya S., Musti A.M., Bamberg E., et al. Channelrhodopsin-1: A light-gated proton channel in green algae. Science 2002, 296(5577):2395-2398. 10.1126/science.1072068.
41. Nagel G., Szellas T., Huhn W., Kateriya S., Adeishvili N., Berthold P., et al. Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(24):13940-13945. 10.1073/pnas.1936192100.
42. Nathanson J.L., Jappelli R., Scheeff E.D., Manning G., Obata K., Brenner S., et al. Short promoters in viral vectors drive selective expression in mammalian inhibitory neurons, but do not restrict activity to specific inhibitory cell-types. Frontiers in Neural Circuits 2009, 3:19. 10.3389/neuro.04.019.2009.
43. Nathanson J.L., Yanagawa Y., Obata K., Callaway E.M. Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors. Neuroscience 2009, 161(2):441-450. 10.1016/j.neuroscience.2009.03.032.
44. Oesterhelt D., Meentzen M., Schuhmann L. Reversible dissociation of the purple complex in bacteriorhodopsin and identification of 13-cis and all-trans-retinal as its chromophores. European Journal of Biochemistry/FEBS 1973, 40(2):453-463.
45. O'Shea D.J., Goo W., Diester I., Kalanithi P., Yizhar O., Ramakrishnan C., et al. Optogenetic control of excitatory neurons via a red-shifted opsin in primate premotor cortex. 2011 Neuroscience meeting planner 2011, Society for Neuroscience, Online, Washington, DC, Program No. 306.11/YY22.
46. Paterna J.-C., Feldon J., Büeler H. Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. Journal of Virology 2004, 78(13):6808-6817. 10.1128/JVI.78.13.6808-6817.2004.
47. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.-P., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism 2003, 80(1-2):148-158.
48. Richardson R.M., Kells A.P., Rosenbluth K.H., Salegio E.A., Fiandaca M.S., Larson P.S., et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Molecular Therapy 2011, 19(6):1048-1057. Nature Publishing Group. 10.1038/mt.2011.11.
49. Sanchez C.E., Tierney T.S., Gale J.T., Alavian K.N., Sahin A., Lee J.-S., et al. Recombinant adeno-associated virus type 2 pseudotypes: Comparing safety, specificity, and transduction efficiency in the primate striatum. Laboratory investigation. Journal of Neurosurgery 2011, 114(3):672-680. 10.3171/2010.8.JNS091583.
50. Santhanam G., Ryu S.I., Yu B.M., Afshar A., Shenoy K.V. A high-performance brain-computer interface. Nature 2006, 442(7099):195-198. 10.1038/nature04968.
51. Scanziani M., Häusser M. Electrophysiology in the age of light. Nature 2009, 461(7266):930-939. 10.1038/nature08540.
52. Tan E.M., Yamaguchi Y., Horwitz G.D., Gosgnach S., Lein E.S., Goulding M., et al. Selective and quickly reversible inactivation of mammalian neurons in vivo using the Drosophila allatostatin receptor. Neuron 2006, 51(2):157-170. 10.1016/j.neuron.2006.06.018.
53. Tønnesen J., Sørensen A.T., Deisseroth K., Lundberg C., Kokaia M. Optogenetic control of epileptiform activity. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(29):12162-12167. 10.1073/pnas.0901915106.
54. Torab K., Davis T.S., Warren D.J., House P.A., Normann R.A., Greger B. Multiple factors may influence the performance of a visual prosthesis based on intracortical microstimulation: Nonhuman primate behavioural experimentation. Journal of Neural Engineering 2011, 8(3):035001. 10.1088/1741-2560/8/3/035001.
55. Truccolo W., Donoghue J.A., Hochberg L.R., Eskandar E.N., Madsen J.R., Anderson W.S., et al. Single-neuron dynamics in human focal epilepsy. Nature Neuroscience 2011, 14(5):635-641. 10.1038/nn.2782.
56. Tuchin V.V. Light scattering study of tissues. Physics-Uspekhi 2007, 40(5):495-515. 10.1070/PU1997v040n05ABEH000236.
57. Wang J., Ozden I., Diagne M., Wagner F., Borton D., Brush B., et al. Approaches to optical neuromodulation from rodents to non-human primates by integrated optoelectronic devices 2011, 7525-7528. 10.1109/IEMBS.2011.6091855.
58. Wang J., Wagner F., Borton D.A., Zhang J., Ozden I., Burwell R.D., et al. Integrated device for combined optical neuromodulation and electrical recording for chronic in vivo applications. Journal of Neural Engineering 2012, 9(1):016001. 10.1088/1741-2560/9/1/016001.
59. Whitmer D., de Solages C., Hill B., Yu H., Henderson J.M., Bronte-Stewart H. High frequency deep brain stimulation attenuates subthalamic and cortical rhythms in Parkinson's disease. Frontiers in Human Neuroscience 2012, 6:155. 10.3389/fnhum.2012.00155.
60. Wichmann T., Delong M.R., Guridi J., Obeso J.A. Milestones in research on the pathophysiology of Parkinson's disease. Movement Disorders 2011, 26(6):1032-1041. 10.1002/mds.23695.
61. Yizhar O., Fenno L.E., Davidson T.J., Mogri M., Deisseroth K. Optogenetics in neural systems. Neuron 2011, 71(1):9-34. 10.1016/j.neuron.2011.06.004.
62. Yizhar O., Fenno L.E., Prigge M., Schneider F., Davidson T.J., O'Shea D.J., et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011, 477(7363):171-178. 10.1038/nature10360.
63. Zhang F., Wang L.-P., Boyden E.S., Deisseroth K. Channelrhodopsin-2 and optical control of excitable cells. Nature Methods 2006, 3(10):785-792. 10.1038/nmeth936.
64. Zhao S., Cunha C., Zhang F., Liu Q., Gloss B., Deisseroth K., et al. Improved expression of halorhodopsin for light-induced silencing of neuronal activity. Brain Cell Biology 2008, 36(1-4):141-154. 10.1007/s11068-008-9034-7.